Zacks Investment Research upgraded shares of Obseva (NASDAQ:OBSV) from a sell rating to a hold rating in a research report report published on Thursday morning.
According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “
Several other brokerages have also recently issued reports on OBSV. HC Wainwright set a $25.00 target price on shares of Obseva and gave the company a buy rating in a report on Thursday, January 4th. BMO Capital Markets started coverage on shares of Obseva in a report on Monday, December 4th. They issued an outperform rating and a $20.00 target price for the company. Credit Suisse Group restated a buy rating and issued a $18.00 target price (up previously from $16.00) on shares of Obseva in a report on Tuesday, February 27th. Finally, Leerink Swann increased their price target on shares of Obseva from $17.00 to $18.00 and gave the stock an outperform rating in a research note on Tuesday, February 27th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Obseva has an average rating of Buy and an average target price of $20.00.
Obseva (NASDAQ:OBSV) last issued its earnings results on Friday, March 9th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.08. analysts forecast that Obseva will post -1.92 earnings per share for the current fiscal year.
A number of large investors have recently modified their holdings of OBSV. Iguana Healthcare Management LLC boosted its stake in Obseva by 66.7% during the 3rd quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock worth $407,000 after purchasing an additional 20,000 shares during the period. Sphera Funds Management LTD. boosted its stake in Obseva by 12.4% during the 3rd quarter. Sphera Funds Management LTD. now owns 260,197 shares of the company’s stock worth $2,118,000 after purchasing an additional 28,700 shares during the period. Abingworth LLP acquired a new stake in Obseva during the 3rd quarter worth $3,480,000. Omega Fund Management LLC acquired a new stake in Obseva during the 4th quarter worth $9,760,000. Finally, First Manhattan Co. acquired a new stake in Obseva during the 4th quarter worth $9,760,000. Hedge funds and other institutional investors own 52.62% of the company’s stock.
Obseva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.